Taysha Gene Therapies Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Taysha reported a Q2 net loss of $46.6 million, or $0.13 per share, compared to a net loss of $26.9 million in the prior year, as R&D expenses increased to support BLA-enabling manufacturing initiatives. The company completed a $230 million follow-on offering, boosting cash reserves to $455.4 million and extending its runway into the second half of 2028, well past the anticipated BLA submission and potential approval for TSHA-102.
Key figures
- Revenue
- 0
- Net loss
- 46639000
- Rd expenses
- 38600000
- Cash position
- 455400000
- Offering proceeds
- 230000000
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.